To amend title XVIII of the Social Security Act to require e-prescribing for coverage under part D of the Medicare program of prescription drugs that are controlled substances.

IN THE HOUSE OF REPRESENTATIVES

JULY 28, 2017

Ms. CLARK of Massachusetts (for herself and Mr. MULLIN) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

A BILL

To amend title XVIII of the Social Security Act to require e-prescribing for coverage under part D of the Medicare program of prescription drugs that are controlled substances.

Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Every Prescription Conveyed Securely Act”.
SEC. 2. REQUIRING E-PRESCRIBING FOR COVERAGE OF COVERED PART D CONTROLLED SUBSTANCES.

(a) IN GENERAL.—Section 1860D–4(e) of the Social Security Act (42 U.S.C. 1395w–104(e)) is amended by adding at the end the following:

“(7) REQUIREMENT OF E-PRESCRIBING FOR CONTROLLED SUBSTANCES.—

“(A) IN GENERAL.—Subject to subparagraph (B), a prescription for a covered part D drug under a prescription drug plan (or under an MA–PD plan) for a schedule II, III, IV, or V controlled substance shall be transmitted by a health care practitioner electronically in accordance with an electronic prescription drug program that meets the requirements of paragraph (2).

“(B) EXCEPTION FOR CERTAIN CIRCUMSTANCES.—The Secretary shall, pursuant to rulemaking, specify circumstances with respect to which the Secretary may waive the requirement under subparagraph (A), with respect to a covered part D drug, including in the case of—
“(i) a prescription issued when the prescriber and dispenser are the same entity;

“(ii) a prescription issued that cannot be transmitted electronically due to the constraints of the most recently implemented version of the National Council for Prescription Drug Programs SCRIPT Standard;

“(iii) a prescription issued by a practitioner who has received a waiver or a renewal thereof for a specified period determined by the Secretary, not to exceed one year, from the requirement to use electronic prescribing, pursuant to a process established by regulation by the Secretary, due to demonstrated economic hardship, technological limitations that are not reasonably within the control of the practitioner, or other exceptional circumstance demonstrated by the practitioner;

“(iv) a prescription issued by a practitioner under circumstances in which, notwithstanding the practitioner’s ability to make an electronic prescription as required
by this subsection, such practitioner reason-
reasonably determines that it would be im-
practical for the individual involved to ob-
tain substances prescribed by electronic
prescription in a timely manner, and such
delay would adversely impact the individ-
ual’s medical condition involved;

“(v) a prescription issued by a practi-
tioner allowing for the dispensing of a non-
patient specific prescription pursuant to a
standing order, approved protocol for drug
therapy, collaborative drug management,
or comprehensive medication management,
in response to a public health emergency,
or other circumstances where the practi-
tioner may issue a non-patient specific pre-
scription;

“(vi) a prescription issued by a practi-
tioner prescribing a drug under a research
protocol; and

“(vii) a prescription issued by a prac-
titioner for a drug for which the Food and
Drug Administration requires the prescrip-
tion to contain certain elements that are
not able to be accomplished with electronic
prescribing such as, a drug with risk evaluation and mitigation strategies that include elements to assure safe use.

“(C) DISPENSING.—Nothing in this paragraph shall be construed as requiring a sponsor of a prescription drug plan under this part, MA organization offering an MA–PD plan under part C, or a pharmacist to verify that a practitioner, with respect to a prescription for a covered part D drug, has a waiver (or is otherwise exempt) under subparagraph (B) from the requirement under subparagraph (A). Nothing in this paragraph shall be construed as affecting the ability of the plan to cover or the pharmacists' ability to continue to dispense covered part D drugs from otherwise valid written, oral or fax prescriptions that are consistent with laws and regulations.

“(D) ENFORCEMENT.—The Secretary shall, pursuant to rulemaking, have authority to enforce and specify appropriate penalties for non-compliance with the requirement under subparagraph (A).”.
(b) **Effective Date.**—The amendment made by subsection (a) shall apply to coverage of drugs prescribed on or after January 1, 2020.